PubMed HealthSearch

Biomedical subjects

R Maurice

Publications and source records attributed to R Maurice.

8 recordsLinked to original sources

Molecular characterization of two monoclonal antibodies specific for the LDL receptor-binding site of human apolipoprotein E.

Apolipoprotein E (apoE), a 299 amino acid protein, is a ligand for the low density lipoprotein receptor (LDLr). It has been established that basic amino acids situated between apoE residues 136 and 150 participate in the interaction of apoE with the LDLr. Evidence suggests that apoE is heterogeneous on lipoproteins in its conformation and in its ability to react with cell surface receptors. Our goal was to produce mAbs that could serve as conformational probes of the LDLr binding site of apoE. We used a series of apoE variants that have amino acid substitutions at residues 136, 140, 143, 144, 145, 150, 152, and 158 to identify the epitopes of two anti-human apoE monoclonal antibodies (mAbs), 1D7 and 2E8, that inhibit apoE-mediated binding to the LDLr. We show that most of the variants that have reduced reactivity with the LDL receptor also have reduced reactivity with the mAbs. The epitopes for both mAbs appear to include residues 143 through 150 and thus coincide with the LDLr-binding site of apoE. It is notable that mAb 2E8, but not 1D7, resembles the LDLr in showing a reduced reactivity with apoE (Arg158 --> Cys). While most of the receptor-defective variants involve replacement of apoE residues directly implicated in binding, substitution of Arg158 by Cys is thought to indirectly affect binding of apoE to the LDLr by altering the conformation of the receptor-binding site. To determine whether the similarity in specificities of the mAbs and the LDLr reflect structural similarities, we cloned and characterized the cDNAs encoding the light and heavy chains of both mAbs. Primary sequence analysis revealed that, although these two antibodies react with overlapping epitopes, their respective complementarity determining regions (CDRs) share little homology, especially those of their heavy chains. The two mAbs, therefore, likely recognize different epitopes or topologies within a limited surface of the apoE molecule. Four negatively charged amino acids were present in the second CDR of the 2E8 heavy chain that could be approximately aligned with acidic amino acids within the consensus sequence of the LDLr ligand-binding domain. This could indicate that mAb 2E8 and the LDLr use a common mode of interaction with apoE.

Amino Acid Sequence

Welfare and the intensive production of rabbits.

Rabbit production in Europe is concentrated largely in the "Latin" countries of Italy, France and Spain, in which animal protectionist attitudes are considered moderate. However, in the case of rabbits, the intensification of husbandry necessitates strict observance of physiological, behavioural and health requirements, in view of the very special needs of the species and the sensitivity of rabbits to environmental conditions. Rabbits are described as anxious, timid and emotional, with unusual arrangements for reproduction (induced ovulation) and digestion (caecotrophy). Therefore, these animals could not be reared intensively until the completion of extensive research, which has been conducted over the past twenty years, into the environmental and nutritional needs of rabbits, and the selection of lines having a calm temperament and maternal aptitude. This research was required to meet the welfare needs of this species. These concepts are perfectly integrated into the current operation of intensive units, and should not be brought into question on the basis of fragmentary observations by some researchers who would wish to see a return to rearing on litter. A discussion of rabbit welfare conducted in 1992 by specialists of the German branch of the World Rabbit Science Association approved modern methods of keeping rabbits on wire grids, provided that some changes were made to current procedures.

Animal Feed

The use of monoclonal antibodies to localize the low density lipoprotein receptor-binding domain of apolipoprotein B.

Human apolipoprotein (apo) B-100 is composed of 4536 amino acids. It is thought that the binding of apoB to the low density lipoprotein (LDL) receptor involves an interaction between basic amino acids of the ligand and acidic residues of the receptor. Three alternative models have been proposed to describe this interaction: 1) a single region of apoB is involved in receptor binding; 2) groups of basic amino acids from throughout the apoB primary structure act in concert in apoB receptor binding; and 3) apoB contains multiple independent binding regions. We have found that monoclonal antibodies (Mabs) specific for a region that spans a thrombin cleavage site at apoB residue 3249 (T2/T3 junction) totally blocked LDL binding to the LDL receptor. Mabs specific for epitopes outside this region had either no or partial ability to block LDL binding. In order to define the region of apoB directly involved in the interaction with the LDL receptor we have tested 22 different Mabs for their ability to bind to LDL already fixed to the receptor. A Mab specific for an epitope situated between residues 2835 and 2922 could bind to its epitope on LDL fixed to its receptor whereas a second epitope between residues 2980 and 3084 is inaccessible on receptor-bound LDL. A series of epitopes near residue 3500 of apoB is totally inaccessible, and another situated between residues 4027 and 4081 is poorly accessible on receptor-bound LDL. In contrast, an epitope that is situated between residues 4154 and 4189 is fully exposed. Mabs specific for epitopes upstream and downstream of the region 3000-4000 can bind to receptor-bound LDL with a stoichiometry close to unity. Our results strongly suggest that the unique region of apoB directly involved in the LDL-receptor interaction is that of the T2/T3 junction.

Antibodies, Monoclonal

A potential complication in the use of monoclonal antibodies: inhibition of apoB-mediated receptor binding by an anti-apoE antibody.

Monoclonal antibody (Mab) 1D7 is specific for human apolipoprotein (apo) E and blocks binding of lipid-associated apoE to the low density lipoprotein (LDL) receptor. We report here that 1D7 can also block the binding of apoE-free LDL to the LDL receptor. The inhibition of LDL-receptor binding is not due to immunological cross-reactivity between the anti-apoE Mab and apoB, the ligand responsible for the interaction of LDL with the LDL receptor: 1) Mab 1D7 did not react with apoE-depleted LDL; 2) the LDL receptor binding inhibitory activity of 1D7 immunoglobulin G (IgG) preparations could be dissociated from the anti-apoE activity; 3) the inhibition was maintained when the fibroblasts were preincubated with the 1D7 IgG, extensively washed, and only then exposed to 125I-labeled LDL. Rather, it appears that 1D7 recognizes mouse apoE, that mouse apoE-1D7 immune complexes contaminate 1D7 IgG preparations and that the contaminating mouse apoE can compete with 125I-labeled LDL for the LDL receptor. We have demonstrated mouse apoE in IgG preparations of 1D7 but not in those of other anti-apoE Mabs that do not influence LDL-receptor binding. Precipitation of 1D7 IgG with NH4SO4 eliminates both apoE and the capacity of 1D7 to block LDL receptor binding. Finally, mouse apoE can be isolated by immunoaffinity chromatography of mouse serum on immobilized 1D7 Mab. As this is probably not a unique case, the observation has important implications for the use of Mabs as structural probes.

Antibodies, Monoclonal

Oscillatory potentials as a marker for dopaminergic disease.

In an effort to find electrophysiologic correlates of dopaminergic disease in man, we measured oscillatory potentials of the electroretinogram in normal and unmedicated schizophrenic subjects, and in rabbits given D1 agonist or antagonist drugs. We found highly reproducible oscillatory potentials in twelve male schizophrenics that were indistinguishable from those in nine male normal volunteers. We also found little electroretinographic difference among four rabbits given intramuscular injections of SKF 38393 (a D1 agonist) and four control animals injected with saline. However, four animals given SCH 23390 (a D1 antagonist) showed diminution of the b-wave and selective suppression of the second oscillatory potential. This effect was more prominent in oscillatory potentials generated by 5-Hz flicker than by a single flash. These rabbit data suggest that further efforts at finding clinical correlations may be worthwhile, possibly with trial of flicker oscillatory potentials, and they support the concept that different oscillatory potentials have different generators.

2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-ben